GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

ravulizumab   Click here for help

GtoPdb Ligand ID: 10168

Synonyms: ALXN-1210 | ALXN1210 | ravulizumab-cwvz | Ultomiris®
Approved drug Immunopharmacology Ligand
ravulizumab is an approved drug (FDA (2018), EMA (2019))
Compound class: Antibody
Comment: Ravulizumab (ALXN1210; Ultomiris) is a humanized monoclonal antibody that binds to human complement component C5. It was developed by Alexion as a next-generation anti-C5 therapy for paroxysmal nocturnal hemoglobinuria (PNH) that was engineered from their already approved PNH agent eculizumab (Soliris), but was designed to have an inherently longer circulating half-life so as to extend dosing intervals to once/month [3].
Peptide sequence and secondary structural information for this antibody are available from its IMGT/mAb-DB record.
Classification Click here for help
Compound class Antibody
Approved drug? Yes. EU EMA (2019)  |  US FDA (2018)
International Nonproprietary Names Click here for help
INN number INN
10659 ravulizumab
Synonyms Click here for help
ALXN-1210 | ALXN1210 | ravulizumab-cwvz | Ultomiris®
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 674
Other databases
GtoPdb PubChem SID 381118878
Search PubMed clinical trials ravulizumab
Search PubMed titles ravulizumab
Search PubMed titles/abstracts ravulizumab